• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

AT1 阻断减轻动脉粥样硬化斑块不稳定性,并伴有载脂蛋白 E 缺陷小鼠组织蛋白酶 S 活性的抑制。

AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice.

机构信息

Department of Anatomy and Neuroscience, Hamamatsu University School of Medicine, 1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.

出版信息

Atherosclerosis. 2010 Jun;210(2):430-7. doi: 10.1016/j.atherosclerosis.2009.12.031. Epub 2010 Jan 4.

DOI:10.1016/j.atherosclerosis.2009.12.031
PMID:20079903
Abstract

Although it has been suggested that the renin-angiotensin (RA) system and cathepsins contribute to the development and vulnerability of atherosclerotic plaque, the interaction of the RA system and cathepsins is unclear. Thus, we investigated the effects of an angiotensin II type 1 receptor (AT1) antagonist, olmesartan, on the levels of cathepsins in brachiocephalic atherosclerotic plaque and plaque stabilization in apolipoprotein E (apoE)-deficient mice receiving a high-fat diet. Under a high fat diet, treatment with olmesartan (3 mg/kg per day) maintained collagen and elastin at high levels and attenuated the plaque development and cathepsin S (Cat S) level in the atherosclerotic plaque of apoE-deficient mice. The administration of olmesartan suppressed the accumulation of macrophages in plaque. Immunoreactivities of Cat S and AT1 were observed in macrophages. The amount of Cat S mRNA and the macrophage-mediated collagenolytic and elastolytic activities in cultured macrophages were increased by exposure to angiotensin II (Ang II), and these effects were diminished by olmesartan and the NADPH-oxidase inhibitor apocynin. These results suggested that Cat S derived from macrophages is involved in the mechanisms of atherosclerotic plaque vulnerability, and AT1 blocker maintained the plaque stabilization alongside the suppression of Cat S and macrophage activities.

摘要

尽管有人提出肾素-血管紧张素(RA)系统和组织蛋白酶参与了动脉粥样硬化斑块的形成和易损性,但 RA 系统和组织蛋白酶之间的相互作用尚不清楚。因此,我们研究了血管紧张素 II 型 1 型受体(AT1)拮抗剂奥美沙坦对载脂蛋白 E(apoE)缺陷小鼠接受高脂肪饮食时肱动脉粥样硬化斑块中组织蛋白酶水平和斑块稳定性的影响。在高脂肪饮食下,奥美沙坦(每天 3 毫克/千克)治疗可维持胶原和弹性蛋白的高水平,并减弱 apoE 缺陷小鼠动脉粥样硬化斑块的斑块形成和组织蛋白酶 S(Cat S)水平。奥美沙坦可抑制斑块中巨噬细胞的积聚。在巨噬细胞中观察到 Cat S 和 AT1 的免疫反应性。暴露于血管紧张素 II(Ang II)可增加培养的巨噬细胞中 Cat S mRNA 的量以及巨噬细胞介导的胶原酶和弹性蛋白酶活性,而奥美沙坦和 NADPH 氧化酶抑制剂 apocynin 可减弱这些作用。这些结果表明,源自巨噬细胞的 Cat S 参与了动脉粥样硬化斑块易损性的机制,AT1 阻滞剂除了抑制 Cat S 和巨噬细胞活性外,还能维持斑块稳定。

相似文献

1
AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice.AT1 阻断减轻动脉粥样硬化斑块不稳定性,并伴有载脂蛋白 E 缺陷小鼠组织蛋白酶 S 活性的抑制。
Atherosclerosis. 2010 Jun;210(2):430-7. doi: 10.1016/j.atherosclerosis.2009.12.031. Epub 2010 Jan 4.
2
Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.血管紧张素受体 1 型阻滞剂可减少载脂蛋白 E 缺陷小鼠的内膜血管新生和斑块生长。
Hypertension. 2011 May;57(5):981-9. doi: 10.1161/HYPERTENSIONAHA.110.168385. Epub 2011 Apr 4.
3
Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.载脂蛋白E基因敲除小鼠中血管紧张素II 2型受体缺失加剧动脉粥样硬化。
Circulation. 2005 Sep 13;112(11):1636-43. doi: 10.1161/CIRCULATIONAHA.104.525550. Epub 2005 Sep 6.
4
Renin inhibition reduces atherosclerotic plaque neovessel formation and regresses advanced atherosclerotic plaques.肾素抑制可减少动脉粥样硬化斑块新生血管形成,并使晚期动脉粥样硬化斑块消退。
Atherosclerosis. 2014 Dec;237(2):739-47. doi: 10.1016/j.atherosclerosis.2014.10.098. Epub 2014 Oct 30.
5
Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.AT1受体阻滞剂奥美沙坦和雌激素通过抗氧化应激对动脉粥样硬化的抑制作用
Hypertension. 2005 Apr;45(4):545-51. doi: 10.1161/01.HYP.0000157409.88971.fc. Epub 2005 Feb 21.
6
Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice.载有吡格列酮的纳米颗粒通过调节载脂蛋白E基因敲除小鼠单核细胞/巨噬细胞分化来预防斑块不稳定和破裂。
Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):491-500. doi: 10.1161/ATVBAHA.115.307057. Epub 2016 Jan 28.
7
Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice.组织蛋白酶 S 的药理学抑制可减少 Apoe-/- 小鼠的动脉粥样硬化病变。
J Cardiovasc Pharmacol. 2010 Jul;56(1):98-105. doi: 10.1097/FJC.0b013e3181e23e10.
8
Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.奥美沙坦,一种新型的血管紧张素 II 型 1 型受体拮抗剂,可降低载脂蛋白 E 缺乏小鼠动脉粥样硬化的严重程度,减少超氧化物的产生。
Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):672-8. doi: 10.1016/j.numecd.2009.12.016. Epub 2010 Apr 15.
9
Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.抑制肾素-血管紧张素系统可减轻血管外膜炎症,减少动脉粥样硬化病变形成。
Biomed Pharmacother. 2009 Dec;63(10):754-61. doi: 10.1016/j.biopha.2009.02.006. Epub 2009 Mar 10.
10
[Impact of olmesartan medoxomil on atherosclerosis lesions in apolipoprotein E knockout mice].奥美沙坦酯对载脂蛋白E基因敲除小鼠动脉粥样硬化病变的影响
Zhonghua Yi Xue Za Zhi. 2016 Aug 16;96(31):2502-6. doi: 10.3760/cma.j.issn.0376-2491.2016.31.013.

引用本文的文献

1
Vascular Extracellular Matrix in Atherosclerosis.血管细胞外基质在动脉粥样硬化中的作用
Int J Mol Sci. 2024 Nov 8;25(22):12017. doi: 10.3390/ijms252212017.
2
Overview of multifunctional cysteinyl cathepsins in atherosclerosis-based cardiovascular disease: from insights into molecular functions to clinical implications.基于动脉粥样硬化的心血管疾病中多功能半胱氨酸组织蛋白酶概述:从分子功能洞察到临床意义
Cell Biosci. 2023 May 19;13(1):91. doi: 10.1186/s13578-023-01040-4.
3
Cysteinyl cathepsins in cardiovascular diseases.半胱氨酸蛋白酶在心血管疾病中的作用。
Biochim Biophys Acta Proteins Proteom. 2020 Apr;1868(4):140360. doi: 10.1016/j.bbapap.2020.140360. Epub 2020 Jan 9.
4
Cathepsin S Deficiency Mitigated Chronic Stress-Related Neointimal Hyperplasia in Mice.组织蛋白酶 S 缺乏减轻了小鼠慢性应激相关的新生内膜增生。
J Am Heart Assoc. 2019 Jul 16;8(14):e011994. doi: 10.1161/JAHA.119.011994. Epub 2019 Jul 12.
5
Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease.组织蛋白酶S作为慢性肾脏病中心血管炎症和钙化的抑制剂
Front Cardiovasc Med. 2018 Jan 5;4:88. doi: 10.3389/fcvm.2017.00088. eCollection 2017.
6
α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol.α-防御素可诱导低密度脂蛋白(LDL)的翻译后修饰,在血浆胆固醇正常水平时促进动脉粥样硬化。
J Biol Chem. 2016 Feb 5;291(6):2777-86. doi: 10.1074/jbc.M115.669812. Epub 2015 Oct 30.
7
Hypoperfusion of the Adventitial Vasa Vasorum Develops an Abdominal Aortic Aneurysm.外膜滋养血管灌注不足会引发腹主动脉瘤。
PLoS One. 2015 Aug 26;10(8):e0134386. doi: 10.1371/journal.pone.0134386. eCollection 2015.
8
Impact of circulating cathepsin K on the coronary calcification and the clinical outcome in chronic kidney disease patients.循环组织蛋白酶K对慢性肾脏病患者冠状动脉钙化及临床结局的影响。
Heart Vessels. 2016 Jan;31(1):6-14. doi: 10.1007/s00380-014-0570-z. Epub 2014 Aug 24.
9
Increased serum cathepsin K in patients with coronary artery disease.冠状动脉疾病患者血清组织蛋白酶K水平升高。
Yonsei Med J. 2014 Jul;55(4):912-9. doi: 10.3349/ymj.2014.55.4.912.
10
Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.心血管代谢疾病中的蛋白酶:病理生理学、分子机制及临床应用
Biochim Biophys Acta. 2015 Feb;1852(2):195-208. doi: 10.1016/j.bbadis.2014.04.032. Epub 2014 May 9.